To see only press releases which have been disclosed pursuant to legislation or other regulations, please select “Regulatory releases” below.
Initiator Pharma’s pudafensine preclinical pharmacology results published in the British Journal of Pharmacology
Initiator Pharma A/S, a clinical-stage biotech company, today announced that an article titled “A novel reuptake inhibitor induces erection by increasing central dopamine and peripheral nitric oxide release” was published in the prestigious peer-reviewed scientific journal British Journal of Pharmacology.
Initiator Pharma expands its position to a broader Sexual Health Franchise and intensifies its business development efforts
Initiator Pharma A/S, a clinical-stage pharma company developing innovative drugs targeting key unmet medical needs within the central and peripheral nervous system, announced today that the company will expand the position of the company to a broader Sexual Health Franchise including both male Erectile Dysfunction (ED) and Female Sexual Dysfunction (FSD) indications. Initiator Pharma will be in San Francisco to present the company at business and investor meetings during the 42nd Annual J.P. Morgan Healthcare Conference January 8 to 11.